Related Experiment Video
Updated: May 6, 2026
06:13
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
27.2K
Intraaortic balloon assistance in intractable cardiogenic shock
European Heart Journal
|May 1, 1986
Summary
Intraaortic counterpulsation (IABP) may improve survival in patients with severe cardiogenic shock post-myocardial infarction when conventional treatments fail. This study suggests IABP offers a life-saving option for intractable cases.
Area of Science:
- Cardiology
- Critical Care Medicine
- Medical Devices
Background:
- Severe cardiogenic shock post-myocardial infarction (MI) has a high mortality rate.
- The effectiveness of intraaortic counterpulsation (IABP) in such cases remains debated due to limited controlled data.
Purpose of the Study:
- To evaluate the efficacy of intraaortic counterpulsation (IABP) in patients with severe, intractable cardiogenic shock following acute myocardial infarction.
Main Methods:
- Observational study of 52 patients with severe cardiogenic shock post-MI.
- Comparison of outcomes between patients treated with IABP and those receiving conventional therapy or non-functioning IABP devices.
Main Results:
- Only 3 of 52 patients improved with conventional treatment alone.
- Of 34 patients treated with IABP for intractable shock, 10 survived longer than one month.
- None of the 15 control patients with non-functioning IABP survived.
Conclusions:
- Intraaortic counterpulsation (IABP) can be a life-saving intervention for patients with severe, protracted cardiogenic shock unresponsive to other treatments.
- IABP demonstrates potential benefit in a high-risk patient population where conventional therapies have failed.
More Related Videos
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.7K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
01:29Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761